AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9151591 — intervention group
Group type: COMPARATOR
Intervention: Immediate implants without guided tissue regeneration (Control group 1)
Number of subjects: 41
Study 9151591 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure implants (Control group 2)
Number of subjects: 41
Study 1331020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg every 12 h for 7-14 days
Number of subjects: 564
Study 1331020 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 750 mg every 12 h for 7-14 days
Number of subjects: 564
Study 1331020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 564
Study 1331020 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 564
Study 1331020 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin with concomitant theophylline
Number of subjects: 564
Study 1331020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin with concomitant theophylline
Number of subjects: 564
Study 3805302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mult
Number of subjects: 60
Study 3805302 — intervention group
Group type: COMPARATOR
Intervention: MMPI
Number of subjects: 60
Study 30230245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models during lectures
Number of subjects: 60
Study 30230245 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture with 2D images
Number of subjects: 60
Study 27987510 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping DLT with tracheal orifice aligned with the concave aspect of the distal curvature (group U)
Number of subjects: 136
Study 27987510 — intervention group
Group type: COMPARATOR
Intervention: Shaping DLT with tracheal orifice aligned with the convex aspect of the distal curvature (group T)
Number of subjects: 136
Study 24835519 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned GP visits
Number of subjects: 150
Study 24835519 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned GP visits
Number of subjects: 150
Study 24835519 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice for unplanned visits
Number of subjects: 150
Study 24835519 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice for planned visits
Number of subjects: 150
Study 22662602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ceftazidime within 60 minutes prior to surgery
Number of subjects: 200
Study 22662602 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (10 ml isotonic sodium chloride 0.9% solution)
Number of subjects: 200
Study 19659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Office care temporary denture reliners (OR)
Number of subjects: 34
Study 19659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care temporary denture reliners (HR)
Number of subjects: 34
Study 18355134 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once-daily in the evening
Number of subjects: 20
Study 18355134 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% in Gelrite once-daily in the morning
Number of subjects: 20
Study 16918588 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg) plus rosiglitazone (2 mg), administered as one capsule twice daily
Number of subjects: 200
Study 16918588 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 200
Study 12962761 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + CsA
Number of subjects: 95
Study 12962761 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + CsA + Basiliximab
Number of subjects: 95
Study 12962761 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + Tacrolimus + Basiliximab
Number of subjects: 95
Study 10758071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy alone or in combination with sertraline
Number of subjects: 45
Study 10758071 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 45
Study 8690565 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal ECMO
Number of subjects: 0
Study 8690565 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 1432554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-naso-pharyngeal suction (S Group)
Number of subjects: 40
Study 1432554 — intervention group
Group type: COMPARATOR
Intervention: No oro-naso-pharyngeal suction (NS Group)
Number of subjects: 40
Study 3883559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid regimen with 3.5% amino acids, 20% fat, and 2.5% glucose
Number of subjects: 12
Study 3883559 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluid regimen with 3.5% amino acids and 20% fat alone
Number of subjects: 12
Study 3883559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 31790905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (statins, ezetimibe)
Number of subjects: 11066
Study 31790905 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10 mg/dL higher LDL-C value
Number of subjects: 11066
Study 28481434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg
Number of subjects: 0
Study 28481434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23418932 — intervention group
Group type: EXPERIMENTAL
Intervention: System of care delivered by stroke care coordinators
Number of subjects: 800
Study 23418932 — intervention group
Group type: COMPARATOR
Intervention: Current practice in stroke services (Control)
Number of subjects: 800
Study 23265919 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE-HIV intervention
Number of subjects: 40
Study 23265919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21319354 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with low dose fentanyl (PF group)
Number of subjects: 32
Study 21319354 — intervention group
Group type: COMPARATOR
Intervention: Midazolam combined with low dose fentanyl (MF group)
Number of subjects: 32
Study 19101790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of targeted agents (specific agents not mentioned)
Number of subjects: 0
Study 19101790 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine pathway inhibition
Number of subjects: 0
Study 19101790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor pathway inhibition
Number of subjects: 0
Study 16879516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 43
Study 16879516 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DLS)
Number of subjects: 43
Study 16879516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FOB and DLS
Number of subjects: 43
Study 12596015 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (44 microg subcutaneous Rebif once weekly)
Number of subjects: 717
Study 10854087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS, 30 mg
Number of subjects: 20
Study 10854087 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine, 4 mg
Number of subjects: 20
Study 10854087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9180716 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured saline-filled implants
Number of subjects: 21
Study 9180716 — intervention group
Group type: COMPARATOR
Intervention: Smooth saline-filled implants
Number of subjects: 21
Study 1524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen daily for 2 years
Number of subjects: 2230
Study 1524921 — intervention group
Group type: COMPARATOR
Intervention: Control (perioperative cyclophosphamide)
Number of subjects: 2230
Study 1524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 2230
Study 4091243 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 30
Study 4091243 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 30
Study 4091243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Doppler echocardiography
Number of subjects: 30
Study 4091243 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, enflurane, isoflurane (MAC 1.0 and 1.5)
Number of subjects: 30
Study 29369673 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message intervention (Message 1: personalized normative feedback, Message 2: protective behavioral strategies)
Number of subjects: 200
Study 29369673 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message intervention
Number of subjects: 200
Study 29369673 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 200
Study 28436722 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise training (36 sessions)
Number of subjects: 20
Study 24552352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 46
Study 24552352 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 46
Study 22619366 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of gluten/day
Number of subjects: 20
Study 22619366 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g of gluten/day
Number of subjects: 20
Study 22619366 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g or 7.5 g of gluten/day
Number of subjects: 20
Study 21071509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-Ratio (4.5% fructose, 9% maltodextrin)
Number of subjects: 10
Study 21071509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8-Ratio (6% fructose, 7.5% maltodextrin)
Number of subjects: 10
Study 21071509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25-Ratio (7.5% fructose, 6% maltodextrin)
Number of subjects: 10
Study 21071509 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 18298234 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 57
Study 18298234 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study 16568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Long TE spectroscopy using LCModel technique at 1.5 T
Number of subjects: 25
Study 16568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Long TE spectroscopy using LCModel technique at 3 T
Number of subjects: 25
Study 16568428 — intervention group
Group type: COMPARATOR
Intervention: Long TE spectroscopy using LCModel technique
Number of subjects: 25
Study 12817159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10-60 mg/day)
Number of subjects: 76
Study 12817159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 12817159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 76
Study 12817159 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine and Placebo
Number of subjects: 76
Study 10591284 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 579
Study 10591284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (medication management + intensive behavioral treatment)
Number of subjects: 579
Study 10591284 — intervention group
Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 579
Study 10591284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 579
Study 8606209 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 0.5 mg subcutaneously 6 hourly for 48 hours (group T)
Number of subjects: 22
Study 8606209 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 22
Study 8606209 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (group T)
Number of subjects: 22
Study 2008863 — intervention group
Group type: EXPERIMENTAL
Intervention: 420‐kcal/d liquid diet (n = 12)
Number of subjects: 20
Study 2008863 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200‐kcal/d balanced diet (n = 8)
Number of subjects: 20
Study 2008863 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200‐kcal/d diet (after 16 weeks for both groups)
Number of subjects: 20
Study 2008863 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 obese nondieters)
Number of subjects: 20
Study 7036765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 0
Study 7036765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine in combination with chloroquine
Number of subjects: 0
Study 7036765 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study 31167540 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 0
Study 30184562 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS risk score model
Number of subjects: 4395
Study 30184562 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 4395
Study 30184562 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG
Number of subjects: 4395
Study 30184562 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 4395
Study 30184562 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 4395
Study 26767971 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Malay massage
Number of subjects: 66
Study 26767971 — intervention group
Group type: COMPARATOR
Intervention: Relaxation position (Control)
Number of subjects: 66
Study 24262059 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 38
Study 24262059 — intervention group
Group type: EXPERIMENTAL
Intervention: Footstool position
Number of subjects: 38
Study 24262059 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 38
Study 22278425 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with pasireotide, cabergoline, and ketoconazole over 80 days
Number of subjects: 17
Study 22278425 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 17
Study 21125810 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (250 mg alpha-methyldopa tablet)
Number of subjects: 12
Study 21125810 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (250 mg alpha-methyldopa tablet)
Number of subjects: 12
Study 17640790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 102
Study 17640790 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 102
Study 17640790 — intervention group
Group type: COMPARATOR
Intervention: Control (AG/GG carriers)
Number of subjects: 102
Study 15831508 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (n=79)
Number of subjects: 154
Study 15831508 — intervention group
Group type: COMPARATOR
Intervention: Curettage (n=75)
Number of subjects: 154
Study 15831508 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (successful)
Number of subjects: 154
Study 15831508 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (unsuccessful)
Number of subjects: 154
Study 15831508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 11908635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLf) gargles (100 mg t.i.d.) + oral erythromycin (500 mg t.i.d.)
Number of subjects: 12
Study 11908635 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin (500 mg t.i.d.)
Number of subjects: 12
Study 10408752 — intervention group
Group type: EXPERIMENTAL
Intervention: Care co-ordination
Number of subjects: 77
Study 10408752 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 7744989 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole and thyroxine for a second year (160 patients)
Number of subjects: 330
Study 7744989 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone for a second year (35 patients)
Number of subjects: 330
Study 7744989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (methimazole and thyroxine)
Number of subjects: 330
Study 2033780 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopentone/suxamethonium (Group A)
Number of subjects: 40
Study 2033780 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopentone/pancuronium (Group B)
Number of subjects: 40
Study 2033780 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 40
Study 7305036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 64
Study 31441853 — intervention group
Group type: EXPERIMENTAL
Intervention: Light alcohol drinkers
Number of subjects: 1472
Study 31441853 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with high regular physical activity
Number of subjects: 1472
Study 31441853 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1472
Study 31441853 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged >65 years
Number of subjects: 1472
Study 31441853 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with higher body mass index, presence of metabolic syndrome, and smoking
Number of subjects: 1472
Study 28503781 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (3 mg) after high-fat meal
Number of subjects: 24
Study 28503781 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (3 mg) with ketoconazole (400 mg once daily for 6 days)
Number of subjects: 24
Study 28503781 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (12 mg) with rifampin (600 mg once daily for 9 days)
Number of subjects: 24
Study 28503781 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib (12 mg) with single dose of rifampin
Number of subjects: 24
Study 26370687 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsiveness Index (RI) monitoring
Number of subjects: 74
Study 23353791 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided protocol
Number of subjects: 2949
Study 21401909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.05 ml anti-vascular endothelial growth factor agents
Number of subjects: 40
Study 19786265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 22
Study 19786265 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 22
Study 17156893 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 0
Study 17156893 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study 12607857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus (TBP)
Number of subjects: 0
Study 12607857 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 0
Study 12607857 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0 (EP3)
Number of subjects: 0
Study 12607857 — intervention group
Group type: COMPARATOR
Intervention: Acid-etched (AE)
Number of subjects: 0
Study 10911572 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona manipulated blastocyst stage transfers (n = 24)
Number of subjects: 46
Study 10911572 — intervention group
Group type: COMPARATOR
Intervention: Zona intact blastocyst stage transfers (n = 22)
Number of subjects: 46
Study 9208536 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuangquan 851 Oral Liquor type R
Number of subjects: 303
Study 9208536 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuangquan 851 Oral Liquor type Y
Number of subjects: 303
Study 9208536 — intervention group
Group type: COMPARATOR
Intervention: Qing Chun Bao Oral Liquor
Number of subjects: 303
Study 1339081 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fiber as wheat bran (WB)
Number of subjects: 34
Study 1339081 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g fiber as wheat bran (WB)
Number of subjects: 34
Study 1339081 — intervention group
Group type: COMPARATOR
Intervention: 10 g fiber as vegetable fiber (VF)
Number of subjects: 34
Study 1339081 — intervention group
Group type: COMPARATOR
Intervention: 30 g fiber as vegetable fiber (VF)
Number of subjects: 34
Study 3914314 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery constriction feedback
Number of subjects: 22
Study 3914314 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 22
Study 3914314 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 22
Study 3481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and sulindac
Number of subjects: 25
Study 3481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and piroxicam
Number of subjects: 25
Study 3481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and sulindac
Number of subjects: 25
Study 3481821 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and piroxicam
Number of subjects: 25
Study 3481821 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and placebo
Number of subjects: 25
Study 31788819 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal feedback on performance during meal preparation sessions with an occupational therapist
Number of subjects: 36
Study 31788819 — intervention group
Group type: COMPARATOR
Intervention: Experiential feedback only (control condition) during meal preparation sessions
Number of subjects: 36
Study 29756653 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20
Study 29756653 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (control)
Number of subjects: 20
Study 28086906 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (health promotion package including an information booklet, education sessions, walking group, and resistance band)
Number of subjects: 377
Study 28086906 — intervention group
Group type: COMPARATOR
Intervention: Standard advice (one session)
Number of subjects: 377
Study 28086906 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (health promotion package)
Number of subjects: 377
Study 26164422 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals (MVM)
Number of subjects: 367
Study 26164422 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals plus choline
Number of subjects: 367
Study 26164422 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 367